Intravenous iron gluconate administration increases circulating PAPP-A in hemodialysis patients

Ren Fail. 2005;27(6):707-11. doi: 10.1080/08860220500242868.

Abstract

Background: Pregnancy-associated plasma protein-A (PAPP-A) is a proatherosclerotic molecule, interrelated with oxidative stress in hemodialysis (HD) patients. As intravenous (IV) iron might enhance oxidative stress in HD patients, this study investigates circulating PAPP-A during HD session and after IV iron administration.

Methods: In 20 HD patients, plasma PAPP-A concentration was assessed immunochemically during 2 HD sessions (prior to HD and at 60, 130, and 240 min of HD session). Sodium ferric gluconate (62.5 mg) was given IV to all patients 65 min after the start of the second HD.

Results: Sixty-five min after IV iron application, there was a significant increase in plasma PAPP-A (from 36.0+/-9.9 to 79.6+/-28.9 mU/L, p<0.0001). At the end of this HD session, PAPP-A decreased significantly (p<0.0001), but still remained 1.5-fold greater compared with predialysis levels (p<0.0005).

Conclusion: IV iron increases circulating PAPP-A, and in this way, it might contribute to more pronounced cardiovascular complications in HD patients.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Analysis of Variance
  • Biomarkers / blood
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / etiology*
  • Female
  • Follow-Up Studies
  • Humans
  • Infusions, Intravenous
  • Iron Compounds / administration & dosage
  • Iron Compounds / adverse effects*
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / therapy*
  • Male
  • Middle Aged
  • Pregnancy-Associated Plasma Protein-A / analysis*
  • Pregnancy-Associated Plasma Protein-A / drug effects
  • Probability
  • Prospective Studies
  • Renal Dialysis / adverse effects*
  • Renal Dialysis / methods
  • Risk Assessment
  • Sensitivity and Specificity
  • Survival Rate
  • Treatment Outcome

Substances

  • Biomarkers
  • Iron Compounds
  • Pregnancy-Associated Plasma Protein-A